ResiDUBs: A deubiquitinating enzyme-based prognostic model identifies UBXN1 driving sorafenib resistance in liver cancer

Key Points

• Sorafenib resistance is significantly driven by the UBXN1 protein, impacting treatment outcomes.
• Key evidence highlights that elevated UBXN1 levels correlate with increased resistance to sorafenib in liver cancer.
• Analysis of deubiquitinating enzymes was used to model prognostic outcomes related to liver cancer treatments.
• These findings highlight the potential for targeting UBXN1 to overcome sorafenib resistance, requiring further exploration.